RxTrials Institute Drug Pipeline Alert

KaloBios Pharmaceuticals has started a Phase I/II study of KB002 as a potential treatment for persistent asthma.

The placebo-controlled study, which is being conducted at several sites in Australia, will enroll up to 24 patients who will receive KB002 or placebo. Endpoints for the study will include safety, measurements of forced expiratory volume and inflammatory markers.

Geoffrey Yarranton, KaloBios’ chief scientific officer, said the treatment has demonstrated efficacy in animal studies.